checkAd
    Harpoon Therapeutics Regsitered Aktie
    21,200
     
    EUR
    0,00 %
    0,000 EUR
    Letzter Kurs 08.03.24 Tradegate
    21,000
     
    EUR
    241 STK
    Geldkurs 11.03.24
    21,200
     
    EUR
    236 STK
    Briefkurs 11.03.24
    ISIN: US41358P2056 · WKN: A3EUUE · SYM: 5HTA · USA

    Neueste Nachrichten

    HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
    10.01.24 · Business Wire (engl.) · Harpoon Therapeutics Regsitered
    ROUNDUP/Aktien New York Schluss: Dow trotzt Boeing - Nasdaq mit Erholungsrally
    08.01.24 · dpa-AFX · Abercrombie & Fitch Registered (A)
    Aktie verdoppelt sich: Merck plant 700-Millionen-Dollar-Deal: Harpoon Therapeutics im Visier - Aktien explodieren!
    08.01.24 · wallstreetONLINE NewsUpdate · Merck & Co
    HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
    08.01.24 · Business Wire (engl.) · Harpoon Therapeutics Regsitered
    Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
    08.01.24 · Business Wire (engl.) · Merck & Co
    Aktie verdoppelt sich: Merck: Übernahme von Harpoon Therapeutics? Aufschlag von 118 Prozent pro Aktie!
    08.01.24 · wallstreetONLINE Redaktion · Merck & Co
    Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
    05.09.23 · globenewswire · Harpoon Therapeutics Regsitered
    Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
    05.09.23 · globenewswire · Harpoon Therapeutics Regsitered
    Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
    03.08.23 · globenewswire · Harpoon Therapeutics Regsitered
    Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
    01.08.23 · globenewswire · Harpoon Therapeutics Regsitered
    Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
    27.06.23 · globenewswire · Harpoon Therapeutics Regsitered
    Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
    11.05.23 · globenewswire · Harpoon Therapeutics Regsitered